Associates of, and Time to Recovery From, Eosinopenia in Severe COPD Exacerbation

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia. The main aims of the study are to: 1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD 2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD

Eligibility
Participation Requirements
Sex: All
Minimum Age: 35
Healthy Volunteers: f
View:

• Admitted to hospital with primary clinical diagnosis of exacerbation of COPD\*

• Smoking history of at least 10 pack years

• Airflow obstruction: FEV1/FVC ratio \< 0.7 confirmed on historic or inpatient spirometry

• Capacity to give informed consent to participate

• Eosinopenia on admission

• Uneventful recovery\*

⁃ Eosinopenia on admission who do not receive a further course of systemic corticosteroids or require emergency hospital admission for an acute illness in the six weeks following admission to hospital with a severe exacerbation of COPD.

Locations
Other Locations
United Kingdom
Northumbria Healthcare NHS Foundation Trust
RECRUITING
North Shields
Contact Information
Primary
Stephen Bourke, MBChB, PhD
stephen.bourke@nhct.nhs.uk
0191 293 4351
Backup
Peter Ireland, MBBS
peter.ireland@northumbria-healthcare.nhs.uk
Time Frame
Start Date: 2024-01-22
Estimated Completion Date: 2026-07
Participants
Target number of participants: 200
Treatments
Participants with severe exacerbation of COPD and eosinophils < 0.05 x 10^9/L
Participants to be included in the co-primary outcomes for the time to recovery from eosinopenia analysis as well as the analysis to identify independent factors associated with eosinopenia on admission in patients with a severe exacerbation of COPD. This group of participants will also be included in all secondary outcomes.
Participants with severe exacerbation of COPD and eosinophils >= 0.05 x 10^9/L
Participants will be included in the co-primary outcome to identify independent factors associated with eosinopenia on admission in patients with a severe exacerbation of COPD. This group of participants will also be included in some of the secondary outcomes.
Sponsors
Collaborators: Newcastle University, Chiesi UK, GlaxoSmithKline
Leads: Northumbria Healthcare NHS Foundation Trust

This content was sourced from clinicaltrials.gov